Merck Millipore acquires rights for Biotest microbiology products
Merck Millipore now has exclusive rights to sell Biotest microbiology products in Australia and New Zealand.
In 2011, Merck Millipore acquired German company Biotest, an innovative industrial microbiology company with capabilities in ready-to-use media and hygiene monitoring. Its products are targeted at the pharmaceutical and food and beverage segments.
Biotest’s microbiology products, previously marketed by either of their two trading companies, Heipha and Hycon, are now exclusively available through Merck Millipore. Technical support for the products is also offered.
QIMR Berghofer signs strategic partnership with Nakanoshima Qross
QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...
Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director
Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
